AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27143498 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based alcohol prevention program (5 modules received by mail every 4 weeks over 5 months)
Number of subjects: 1349
Study 27143498 — intervention group
Group type: COMPARATOR
Intervention: Control group (factsheet information brochure)
Number of subjects: 1349
Study 23782517 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group (PEG) intervention
Number of subjects: 367
Study 23782517 — intervention group
Group type: COMPARATOR
Intervention: Support group (SG) intervention
Number of subjects: 367
Study 22744517 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts
Number of subjects: 55
Study 22744517 — intervention group
Group type: COMPARATOR
Intervention: Cages (titanium interbody implants)
Number of subjects: 55
Study 20378644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin targets
Number of subjects: 596
Study 20378644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline echocardiograms
Number of subjects: 596
Study 20378644 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP
Number of subjects: 596
Study 20378644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LVMI
Number of subjects: 596
Study 18777992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 408
Study 18777992 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 408
Study 15545235 — intervention group
Group type: EXPERIMENTAL
Intervention: New personal protective eyewear
Number of subjects: 20
Study 15545235 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially aged personal protective eyewear
Number of subjects: 20
Study 15545235 — intervention group
Group type: COMPARATOR
Intervention: Control (no eyewear)
Number of subjects: 20
Study 11744789 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin-I-based protocol
Number of subjects: 400
Study 11744789 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 400
Study 9431711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 3% diclofenac in 2.5% hyaluronic acid gel
Number of subjects: 130
Study 9431711 — intervention group
Group type: COMPARATOR
Intervention: Gel containing 2.5% hyaluronic acid alone
Number of subjects: 130
Study 10129395 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert opinion/group judgement
Number of subjects: 0
Study 10129395 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies (prospective cohort, case control, retrospective studies, cross-sectional, case studies)
Number of subjects: 0
Study 3693756 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorically defined exchange diet (EXCH)
Number of subjects: 51
Study 3693756 — intervention group
Group type: COMPARATOR
Intervention: Unmeasured diet avoiding refined sugars (UNMEAS)
Number of subjects: 51
Study 3693756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate intake (less than 30%)
Number of subjects: 51
Study 29111905 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day CoQ10 supplements
Number of subjects: 50
Study 29111905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26801783 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap measurement
Number of subjects: 120
Study 26801783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation
Number of subjects: 120
Study 25980298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with methotrexate
Number of subjects: 0
Study 25980298 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 0
Study 22817868 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of inhaled Salvinorin A
Number of subjects: 10
Study 22817868 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of inhaled Salvinorin A
Number of subjects: 10
Study 22817868 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of inhaled Salvinorin A (control)
Number of subjects: 10
Study 20113923 — intervention group
Group type: EXPERIMENTAL
Intervention: It's Your Game: Keep it Real (IYG) intervention
Number of subjects: 907
Study 20113923 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 907
Study 18832343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg/d)
Number of subjects: 162
Study 18832343 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin (15 mg/d)
Number of subjects: 162
Study 18832343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 16898488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin A concentration in children with nephrotic syndrome (NS)
Number of subjects: 53
Study 16898488 — intervention group
Group type: COMPARATOR
Intervention: Fetuin A concentration in control group (K)
Number of subjects: 53
Study 16898488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin A concentration in children with chronic renal failure (CRF)
Number of subjects: 53
Study 16898488 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations of fetuin A in children with NS
Number of subjects: 53
Study 16898488 — intervention group
Group type: COMPARATOR
Intervention: Correlations of fetuin A in groups K and CRF
Number of subjects: 53
Study 12810503 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment (50 U per axilla)
Number of subjects: 207
Study 12810503 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 207
Study 12810503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life parameters and satisfaction after BTX‐A treatments
Number of subjects: 207
Study 12810503 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile of BTX‐A
Number of subjects: 207
Study 11014752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low workload condition
Number of subjects: 126
Study 11014752 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium workload condition
Number of subjects: 126
Study 11014752 — intervention group
Group type: EXPERIMENTAL
Intervention: High workload condition
Number of subjects: 126
Study 8780660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-unit donation (206 +/- 10 mL)
Number of subjects: 30
Study 8780660 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-unit donation (414 +/- 21 mL)
Number of subjects: 30
Study 8780660 — intervention group
Group type: COMPARATOR
Intervention: Sham donation
Number of subjects: 30
Study 1621675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diets
Number of subjects: 96
Study 1621675 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted phosphorus diets
Number of subjects: 96
Study 1621675 — intervention group
Group type: COMPARATOR
Intervention: Control diet (not specified)
Number of subjects: 96
Study 1621675 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diet groups
Number of subjects: 96
Study 1621675 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control (not specified)
Number of subjects: 96
Study 6715694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 0
Study 6715694 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 0
Study 6715694 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (enhancement of empathy)
Number of subjects: 0
Study 6715694 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus cognitive-behavioral intervention
Number of subjects: 0
Study 31647843 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25mg intravitreal ziv‐aflibercept (IVZ)
Number of subjects: 20
Study 31647843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg intravitreal ziv‐aflibercept (IVZ)
Number of subjects: 20
Study 27670875 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese spinal orthopedic manipulation (TCSOM)
Number of subjects: 80
Study 27670875 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium Bromide (PBD)
Number of subjects: 80
Study 27839534 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially qualified family companions (experimental intervention)
Number of subjects: 63
Study 27839534 — intervention group
Group type: COMPARATOR
Intervention: Conventional care companions (control intervention)
Number of subjects: 63
Study 23918282 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon treatment
Number of subjects: 40
Study 23918282 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 23163251 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training programme (17-hour programme across 8 weeks)
Number of subjects: 10
Study 23163251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 10
Study 18767928 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 1189
Study 18767928 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg weekly)
Number of subjects: 1189
Study 18767928 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1189
Study 18767928 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 1189
Study 18767928 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab and Alendronate
Number of subjects: 1189
Study 17485150 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant subunit gp350 Epstein-Barr virus vaccine
Number of subjects: 148
Study 15478752 — intervention group
Group type: EXPERIMENTAL
Intervention: Short feedback-processing time condition
Number of subjects: 0
Study 15478752 — intervention group
Group type: EXPERIMENTAL
Intervention: Long feedback-processing time condition
Number of subjects: 0
Study 15478752 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 15478752 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-integration category learning
Number of subjects: 0
Study 11566144 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade with naltrexone (single oral dose)
Number of subjects: 0
Study 11566144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no opioid blockade)
Number of subjects: 0
Study 9861567 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin single daily dosage (20 mg/kg)
Number of subjects: 23
Study 9861567 — intervention group
Group type: COMPARATOR
Intervention: Amikacin twice daily dosage (20 mg/kg)
Number of subjects: 23
Study 7946862 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.06 mg kg‐1)
Number of subjects: 45
Study 7946862 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.2 mg kg‐1 h‐1)
Number of subjects: 45
Study 7946862 — intervention group
Group type: COMPARATOR
Intervention: No sedative drug (group ND)
Number of subjects: 45
Study 3364222 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM)
Number of subjects: 76
Study 3364222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 76
Study 3364222 — intervention group
Group type: COMPARATOR
Intervention: Restrained control (RC)
Number of subjects: 76
Study 3364222 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained control (UC)
Number of subjects: 76
Study 29446174 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment for bulimia nervosa (FBT-BN)
Number of subjects: 110
Study 29446174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adolescents (CBT-A)
Number of subjects: 110
Study 29446174 — intervention group
Group type: COMPARATOR
Intervention: FBT-BN
Number of subjects: 110
Study 29446174 — intervention group
Group type: COMPARATOR
Intervention: CBT-A
Number of subjects: 110
Study 29894613 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in women with moderate preeclampsia (Io group)
Number of subjects: 62
Study 29894613 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in women with severe preeclampsia (II group)
Number of subjects: 62
Study 29894613 — intervention group
Group type: COMPARATOR
Intervention: Control group (I) - 26 nulliparous women undergoing planned Cesarean section
Number of subjects: 62
Study 29894613 — intervention group
Group type: COMPARATOR
Intervention: Control group (IQ) - 22 healthy non-pregnant women
Number of subjects: 62
Study 23529870 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week preventive intervention (n=78)
Number of subjects: 139
Study 23529870 — intervention group
Group type: COMPARATOR
Intervention: self‐study control (n=61)
Number of subjects: 139
Study 23885960 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER intervention (family-based in sixth grade and school-based in seventh grade)
Number of subjects: 11000
Study 23885960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11000
Study 20838357 — intervention group
Group type: COMPARATOR
Intervention: MGP
Number of subjects: 48
Study 20838357 — intervention group
Group type: COMPARATOR
Intervention: IVB (1.25 mg)
Number of subjects: 48
Study 20838357 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB followed by MGP
Number of subjects: 48
Study 18551283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 38
Study 18551283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18551283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress exposure
Number of subjects: 38
Study 17087779 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg FA
Number of subjects: 128
Study 17087779 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg FA
Number of subjects: 128
Study 17087779 — intervention group
Group type: EXPERIMENTAL
Intervention: betaine 100 mg kg(‐1) day(‐1)
Number of subjects: 128
Study 17087779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 17087779 — intervention group
Group type: COMPARATOR
Intervention: placebo (for betaine group)
Number of subjects: 128
Study 12818978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 130
Study 12818978 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 130
Study 12818978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus Ondansetron 4 mg
Number of subjects: 130
Study 15231978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 100
Study 15231978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 100
Study 15231978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10195517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 0.5 mg/kg p.o. 1 hour before surgery
Number of subjects: 57
Study 10195517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 1.0 mg/kg p.o. 1 hour before surgery
Number of subjects: 57
Study 10195517 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 57
Study 7662220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 16
Study 7662220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic method for assessing changes in eye redness
Number of subjects: 17
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of birch pollen
Number of subjects: 17
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of birch pollen (about half the effective dose)
Number of subjects: 17
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires measuring sensory irritation (dryness)
Number of subjects: 17
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic measurement of eye redness
Number of subjects: 17
Study 2323832 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation between eye redness and eye irritation
Number of subjects: 17
Study 6985760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression (six chambers) at pressures of 35, 30, and 20 mm Hg for 12 seconds
Number of subjects: 10
Study 6985760 — intervention group
Group type: COMPARATOR
Intervention: Nonsequential device (one chamber) inflated at 35 mm Hg for 12 seconds
Number of subjects: 10
Study 6985760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression device
Number of subjects: 10
Study 6985760 — intervention group
Group type: COMPARATOR
Intervention: Small-dose subcutaneous heparin
Number of subjects: 10
Study 31536116 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR + counseling
Number of subjects: 327
Study 28627002 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized melanoma genomic risk assessment
Number of subjects: 103
Study 25822543 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiva
Number of subjects: 300
Study 25822543 — intervention group
Group type: COMPARATOR
Intervention: Balloon Kyphoplasty (BK)
Number of subjects: 300
Study 23670326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 32
Study 23670326 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids
Number of subjects: 32
Study 21851905 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cell capturing stents (ECS)
Number of subjects: 1300
Study 21851905 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 1300
Study 19194783 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 150
Study 19194783 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 150
Study 19194783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19194783 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and Raloxifene
Number of subjects: 150
Study 17955843 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed by experienced surgeon (group 1; n=41 eyes)
Number of subjects: 76
Study 17955843 — intervention group
Group type: COMPARATOR
Intervention: Surgery performed by two residents (group 2; n=40 eyes)
Number of subjects: 76
Study 15540912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 1 g given twice a day until occurrence of meningitis or at least 5 days after trauma
Number of subjects: 109
Study 15540912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic medication)
Number of subjects: 109
Study 11552768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere)
Number of subjects: 149
Study 11552768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 9041304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/kg RSVIG
Number of subjects: 107
Study 9041304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 8174569 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosage of 60 mg isosorbide-5-mononitrate
Number of subjects: 37
Study 8174569 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosage of 60 mg isosorbide-5-mononitrate
Number of subjects: 37
Study 3148071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betaine, 3 g b.i.d
Number of subjects: 5
Study 3148071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31488084 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone toxicity management
Number of subjects: 500
Study 31488084 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 500
Study 28654365 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus OFS (TEXT)
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS (TEXT)
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: OFS
Number of subjects: 582
Study 28654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-assigned endocrine therapy
Number of subjects: 582
Study 25474533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 3746
Study 25474533 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in the preceding week
Number of subjects: 3746
Study 25474533 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3746
Study 23939291 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel
Number of subjects: 20
Study 23939291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas‐permeable
Number of subjects: 20
Study 23939291 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK)
Number of subjects: 20
Study 23939291 — intervention group
Group type: COMPARATOR
Intervention: Control (NCCA)
Number of subjects: 20
Study 21751994 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing task
Number of subjects: 88
Study 21751994 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 88
Study 19486959 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 152
Study 19486959 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study 17598141 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management therapy (n = 51)
Number of subjects: 101
Study 17598141 — intervention group
Group type: COMPARATOR
Intervention: Active-control therapy (n = 50)
Number of subjects: 101
Study 15349113 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based curriculum in critical appraisal skills (including clinical and methodologic articles, listserve discussion, critiques)
Number of subjects: 55
Study 15349113 — intervention group
Group type: COMPARATOR
Intervention: Control group (only clinical articles)
Number of subjects: 55
Study 11773150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 100 microg/kg
Number of subjects: 36
Study 11773150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 20 microg/kg
Number of subjects: 36